Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

What is the purpose of this trial?

JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone or in combination with a fixed dose of nivolumab in subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

Participation Guidelines

Ages: 18 years and older

Gender: Both

Jounce Therapeutics

Start Date: 04/12/2017

End Date: 12/01/2020

Last Updated: 07/01/2018

Study HIC#: 1606017922